We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

IMB:LSEImperial Brands PLC Analysis

Data as of 2026-06-14 - not real-time

£2,797.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Imperial Brands is trading below its short‑term moving averages, indicating a price gap that sits under both the 20‑day and 200‑day trendlines, while the broader market trend remains bearish. Technical signals are mixed: the MACD histogram has turned positive, suggesting short‑term momentum may be building, yet the RSI hovers around the mid‑range, offering no clear overbought or oversold bias. The stock’s beta is marginally negative and recent volatility is elevated, reflecting heightened price swings in a defensive sector. Fundamentally, the company delivers a robust dividend yield that ranks among the highest in its peer group, and cash flow generation comfortably covers the payout, pointing to sustainable income. A discounted cash‑flow model places fair value well above the current price, implying a material upside potential without relying on aggressive growth assumptions. Recent earnings highlighted modest revenue growth driven by pricing strength in cigarettes and incremental gains in next‑generation products, reinforcing the dividend narrative.
Analyst sentiment leans bullish with a consensus “Buy” and a median price target above today’s level, while the market’s “Extreme Greed” sentiment may be amplifying short‑term buying pressure. Regulatory headwinds remain a key concern for the tobacco space, but the company’s diversified geographic footprint and strong brand portfolio mitigate some of that risk. The combination of a sizable valuation discount, attractive dividend, and emerging product pipeline supports a cautiously optimistic outlook, especially for investors seeking income and value exposure.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • price discount to DCF fair value
  • high dividend yield with strong cash coverage
  • MACD histogram turning positive

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • steady revenue growth from pricing and NGP expansion
  • continued dividend attractiveness
  • analyst consensus and upside price target

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • persistent regulatory and health‑policy pressures
  • shift toward reduced‑risk products requiring capital investment
  • reliable cash flow supporting dividend but limited growth horizon

Key Metrics & Analysis

Financial Health

Revenue Growth4.90%
Profit Margin8.96%
P/E Ratio13.1
ROE37.15%
ROA7.80%
Debt/Equity243.80
P/B Ratio4.7
Op. Cash Flow£3.5B
Free Cash Flow£2.5B

Technical Analysis

TrendBearish
RSI51.3
Support£2,626.00
Resistance£3,170.00
MA 20£2,775.80
MA 50£2,832.40
MA 200£3,061.67
MACDBullish
VolumeDecreasing
Fear & Greed Index89.86

Valuation

Fair Value£3,918.70
Target Price£3,313.64
Upside/Downside18.47%
GradeUndervalued
TypeBlend
Dividend Yield5.96%

Risk Assessment

Beta-0.18
Volatility27.31%
Sector RiskLow
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.